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ABSTRACT
￿
It has been suggested that products of the major histocompatibility complex, the
MHC, of vertebrates function in many processes of recognition and ligand binding at the cell
surface. Here we show that binding of polyclonal and monoclonal antibodies against human
MHC antigens, HLA, reduced the binding of epidermal growth factor (EGF) to its membrane
receptors on A-431 tumor cells and on normal human fibroblasts. Binding of EGF at 37°C
similarly inhibited the binding of Fab fragments and intact Ig anti-HLA to human cells. The
inhibitory effect of anti-HLA antibodies was rapid and dependent upon temperature and
antibody concentration and valence.
Fluorescence microscopy qualitatively confirmed the binding data and showed that MHC
antigens and EGF-receptors do not co-cluster in the membrane.
A major histocompatibility complex, MHC,' was first identi-
fied in mice as one of many segregating histocompatibility
loci whose products provoke allograft rejection. The antigenic
products of the mouse MHC, H-2, not only provoked vigor-
ous rejection, they also stimulated production of circulating
antibodies, reactive with tissues bearing graft donor alloanti-
gens. These antibodies allowed a fine serological analysis of
H-2 transplantation antigens, and such analysis, together with
results on grafting, indicated that H-2 is highly polymorphic.
Similar approachesin human transplantation, as well as work
with teleost fish, chickens, cattle, and dogs, led to similar
results. Each species possesses a single complex genetic region,
highly polymorphic, whose products are major allograft anti-
gens as well as being detectable by circulating antibodies (12,
33). Hence, the general term major histocompatibility com-
plex, MHC, denotes such a region, in addition to a particular
species name. Genes ofthe MHC specify various cell surface
glycoproteins, some of which (the so-called class II products)
are represented only in immunocytes, while others (class I
products) are present in virtually all nucleated cells.
'Abbreviations used in this paper:
￿
DME, Dulbecco's modified Ea-
gle's medium; EGF, epidermal growth factor, HFF, human foreskin
fibroblasts; MHC, major histocompatibility complex.
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The MHC plays a pivotal role in immune processes. Its
products function in immune responses as targets, as contexts
for recognition of other cell surface antigens, or as sites of
cell-to-cell interactions (reviews in 2, 34). MHC products may
also function in general as contexts for ligand binding and
cell-cell interactions. The MHC functions in immune re-
sponses would be a special case ofthis more general function
(11, 24, 30). MHC haplotype is associated with the number
and affinity of receptors for glucagon and insulin in liver
membranes (18, 19), and influences cell contact and adhesion
in several different systems (1, 10, 38). These associations are
likely to be due to known class I antigens since antibodies to
these antigens inhibit hormone binding (18, 32) and cell
adhesion (1).
Here we use a monoclonal antibody to human class I MHC
antigens, HLA-A, B, C, to probe the interaction of these
antigens with the receptor for epidermal growth factor (EGF)
in intact cells. We show that in two different cell types, A-431
human tumor cells, and normal human fibroblasts, the bind-
ing of antibody to HLA antigens alters the display of EGF
receptors, while binding of EGF to its receptors affects the
binding of antibody to HLA. The interaction between MHC
antigens and the EGF receptor system is rapid and sensitive
to temperature and to antibody valence.
725MATERIALS AND METHODS
Reagents:
￿
EGF was isolated from the submaxillary glands ofadult male
mice according to the procedure of Savage and Cohen (27). EGF was purified
to homogeneity as judged by isoelectric focusing, amino terminal, and total
amino acid analysis. EGF was iodinated by the chloramine-T method (15) to
a specific activity of 105-2 x 105 cpm/ng protein. Rhodamine conjugated EGF
was prepared as described by Schlessinger et al. (28). Human growth hormone
was a generous gift from Dr. Z. Laron (Weizmann Institute) and was iodinated
by a modification of the lactoperoxidase method (5) to a specific activity of4-
8 x 10" cpm/ng protein. Affinity-purified goat anti-mouse Ig was the gift of
Dr. J. Haimovich (Weizmann Institute). Bovine pituitary fibroblast growth
factor was a kind gift of Dr. I. Vlodavski (Weizmann Institute). Concanavalin
4 and wheat germ agglutinin were purchased from Miles-Yeda (Rehovot,
Israel) and iodinated according to published procedures (9). A murine cell line
producing a monoclonal IgG2a, denoted KE-2, was the generous gift of Dr.
Roger Kennett (University ofPennsylvania). KE-2 cells were grown in Eagle's
Minimal Essential Medium, with 10% fetal calf serum (Reheis Chemical Co.).
TheIgGwas purified from spent medium by adsorption to proteinA-Sepharose
at pH 8.5 and elution from the washedcolumn at pH 4.5. The antibodyappears
to be directed to a monomorphic HLA antigenic specificity. It precipitates
material ofM 44,000 and 11,000 from detergent extracts ofa number of cell
lines, including 35S-labeled A431, but does not react with Daudi, a line lacking
surface HLA. The KE-2 preparation was free of EGF contamination asjudged
by a sensitive radioimmunoassay performed with rabbit anti-EGF antibodies.
Monovalent Fab fragments were prepared from KE-2 Ig by brief papain
digestion, following the procedure ofGuyer et al. (13). The Fab were isolated
on Sephadex G-100 and freed from contamination by Fc and intact IgG by
passage over protein A-Sepharose. The KE-2 IgG2a and its monovalent Fab
fragments were iodinated by a modification of the chloramine-T method as
described by Mason and Williams (22) to a specific activity of2-5 x 101, cpm/
kg protein. The labeled proteins were >90% as active as native unlabeled
proteins.
Tetramethylrhodamine and fluorescein conjugates of the KE-2 IgG2a and
its Fab fragments were preparedas describedby Brandtzaeg (4) with tetrameth-
ylrhodamine isohthiocyanate and fluorescein isothiocyanate (Research Organ-
ics, Inc., Cleveland, OH). The molar fluorophore to protein ratio, determined
by absorbance measurements, ranged between 1.5 and 3. A polyclonal anti-
HLA antiserum, Stoltzfus, reacting with >90% ofall individualswasthe gift of
Dr. Wilma Bias (The Johns Hopkins Medical School). An immunoglobulin
fraction of this antiserum was prepared by ammonium sulfate precipitation
followed by DE-52 (Whatman Laboratory Products, Inc., Clifton, NJ) anion
exchange chromatography. The murine monoclonal IgG2a 4113, and 2136,
directed against cell surface components of A-431 cells, were prepared from
hybridomas established in our laboratory by fusion ofNS-1 myeloma cells and
spleen cells of mice immunized with fixed A-431 cells (29). They react with A-
431, human foreskin fibroblasts (HFF), and mouse 3T3 cells, but not with
lymphocytes. They do not precipitate material of the size or with the kinase
activity ofEGF receptor from detergent extracts ofA431 cells.
Cells:
￿
Human epidermoid carcinoma cells (A-431 cell line) were kindly
provided by Dr. G. Todaro (Frederick Cancer Research Center, Frederick,
MD). HFF from primary cultures were a gift from Dr. M. Gabbay (Weizmann
Institute). All cells were grown in Dulbecco's modified Eagle's medium (DME)
containing 10% heat-inactivated fetal calfserum.
Binding Assays:
￿
Cells were grown to confluent monolayers in 24-well
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FIGURE 1 Effect of anti-
HLA IgG and its Fab frag-
ment on EGF binding to
A-431 and HFF cells. A-
431 cells (A) or HFF cells
(B) were preincubated at
37°C for 30 min with either
1 .5 x 10-' M anti-HLA IgG
("), 10-6 M anti-HLA Fab
(A), or buffer W, before
incubation at 4°C for 1 h
with various concentra-
tions of '251-EGF.
Costar trays (Costar. Data Packaging, Cambridge, MA) and incubated with
iodinated ligands following various time and temperature protocols in a final
volume of 0.25 ml ofeither DME containing 0.1 % BSA and buffered at pH
7.4 with HEPES (DME-BSA) or 10 mM phosphate-buffered saline pH 7.4
containing 0.1 % BSA (PBS-BSA). In some experimentscells were prefixed with
neutralized 3% paraformri-dehyde at room temperature. Binding of EGF to
these fixed cells was similar in magnitude to binding to unfixed cells, in
agreement with published work (14). At the end of the incubation, cells were
washed four times with cold buffer, lysed with 0.1 N NaOH, and the cell-
associated radioactivity was determined. Nonspecific binding was assessed in
each assay. Radioactivity bound in the presence of 100-fold excess ofunlabeled
over labeled ligand did not exceed 15% ofspecific binding in any assay.
Fluorescence Microscopy: Cells were plated at low density on
coverslips in 35-mm culture dishes and incubated with fluorescent derivatives
ofEGF or of anti-HLA antibodies in DME-BSA. Cells were observed with a
Zeiss inverted microscope equipped with filters for selective observation of
either fluorescein or rhodamine fluorescence. Photographs were taken on
Kodak Tri-X film.
RESULTS
Anti-HLA Antibodies Reduce Binding of EGF to
A-431 and HFF Cells
Incubation of confluent monolayers oflive A-431 and HFF
cells at 37°C with 1 .5 x 10' M monoclonal IgG anti-HLA,
KE-2, reduced the subsequent level of binding of radiolabeled
EGF at 4°C (Fig. 1). A Scatchard plot analysis indicates that
the A-431 cells bear an apparently homogeneous population
of 1 .5 x 106 EGF receptors per cell and the HFF bear - 105
EGF receptors per cell. Ka, for both receptors is 109 M-I.
Incubation at 37°C with 1 .5 x 10-' M KE-2 IgG reduced the
binding of EGF to A-431 cells by -40% and the binding to
HFF cells by -30% over the whole EGF concentration range
assayed. (Fig. 1). The inhibition of EGF binding was depend-
ent on the concentration of KE-2 IgG (Fig. 2) and was
proportional to the equilibrium binding of MHC antigens by
the antibody (Fig. 3). The inhibitory effect reached a plateau
value at 3 x 10-' M KE-2 IgG and decreased somewhat at
higher antibody concentrations (Fig. 2). Inhibition was most
effective if cells were not washed after binding KE-2 and
before adding EGF. However, significantinhibition ofbinding
(80% ofmaximum inhibition) was seen in washed cells.
Preincubation with Ke-2 IgG at 37°C also decreased EGF
binding to cells at 37°C. At this temperature, EGF induces a
rapid clustering of its membrane receptor (39) followed by
N
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FIGURE 2 Concentration dependence of the effect of anti-HLA
IgG and its Fab fragment on EGF binding to A-431 and HFF Cells.
A-431 cells (open symbols) or HFF cells (closed symbols) were
preincubated at 37°C for 30 min with either anti-HLA IgG (A) or
anti-HLA Fab (0) before incubation at 4°C for 1 h with 2 x 10-9 M
'251-EGF. Data points represent the mean ± standard deviation of
two independent experiments performed in triplicate.internalization and degradation (at different rates for different
target cells) ofthe hormone-receptor complexes (7). The anti-
HLA antibody decreased both the cell surface bound EGF,
assayed by release after mild acetic acid treatment (37), and
the internalized hormone (data not shown).
The effect of the anti-HLA antibody on EGF binding was
almost immediate. Varying preincubation times from 5 min
to 4 h at 37°C with the KE-2 IgG did not significantly alter
the reduction in EGF binding (Table I). Moreover, the anti-
HLA antibody affected the initial rate of binding of 12'I-EGF
to cells at 4°C as well as equilibrium binding. The effect of
KE-2 IgG on EGF binding was not peculiar to this anti-HLA
reagent. A polyclonal monospecific anti-HLA reagent, Stoltz-
fus, inhibited EGF binding to A-431 and HFF cells to about
the same extent as KE-2 IgG (Table I).
Specificity of the Inhibition
Two murine monoclonal IgG2a antibodies (denoted 4B3
and 2136) directed against abundant cell surface components
of A-431 and HFF cells but not against EGF receptors did
not affect the binding of EGF to these cells (Table I). The
KE-2 IgG did not change the number or apparent affinity of
membrane lectin receptors on A-431 and HFF cells (-5 x
Concentration of anti -HLA (Mx10 8 )
FIGURE 3
￿
Binding of anti-HLA IgG and its Fab fragment to A-431
cells and the effect of EGF. A-431 cells were preincubated at 37°C
for 30 min either with buffer (open symbols) or 5 x 10-' M EGF
(closed symbols) before incubation at 4°C for 1 h with either various
concentrations of anti-HLA IgG (O) or anti-HLA Fab (A).
TABLE I
Influence of Various Inhibitors and Incubation Conditions on the
Binding of '2'I-EGF to A-431 Cells
10' receptors per cell), or the number or apparent affinity of
human growth hormone receptors (-2 x 10° per cell).
Requirements for Inhibition of EGF Binding by
Anti-HLA Antibodies
Fab fragments of KE-2 IgG bound readily to A-431 (and
HFF) cells, although with a lower apparent affinity than the
intact antibody (Fig. 3). The Fab fragments did not signifi-
cantly reduce binding ofEGF to its receptors on either A-431
orHFF cells(Fig. 1), even when relatively high concentrations
were used (Fig. 2). EGF binding was inhibited when the cell-
bound KE-2 Fab fragments were cross-linked at 37°C with a
second layer of goat anti-mouse Ig antibodies.
Binding anti-HLA at 4°C or to cells previously fixed in 3%
paraformaldehyde had no effect on subsequent EGF binding.
Though cross-linking of HLA antigens appears to be required,
EGF binding was inhibited by anti-HLA antibodies even in
the presence of 10-5 M cytochalasin D 10-' M colchicine, or
0.1 % NaN3. Thus, although cell metabolism appears to be
required for an effect of anti-HLA on EGF receptol's, aggre-
gation of receptors into caps or large patches is not required.
EGF Reduces Binding ofAnti-HLA Antibodies to
A-431 and HFF Cells
Binding of KE-2 IgG and Fab to A431 and HFF cells was
measured with iodinated Ig and Fab (Fig. 3). There were -2
x 106 HLA molecules per A-431 cell and approximately one-
tenth this number on HFF. Kapp of the Ig was -2 x 10' M-'
and that ofthe Fab -3 x 106 M-' . Scatchard plot analysis of
the data ofFig. 3 showed that about 1 .5-fold more Fab bound
to A431 cells than did IgG. Thus, about one-half of the Ig
was bound to two HLA molecules and halfwas bound to one
HLA molecule. The ratio of Fab bound/IgG bound is ex-
pected to range between 1, when all IgG is bound by one
combining site only, to 2, when all IgG is bound divalently,
by both combining sites(22). Incubation ofcellsat 37°C with
EGF reduced the number of sites occupied by the Ig or its
Fab but did not alter their apparent affinities for HLA. The
ratioof Fab bound to IgG bound in the presence of EGF was
-2. Hence all of the IgG bound to HLA in the presence of
EGF was bound divalently.
The inhibition of anti-HLA ligand binding mediated by
Confluent monolayers of A-431 in 24-well Costar trays were preincubated under various conditions before addition of 10 ng/ml'zsl-EGF at 4°C for 1 h and
determination of the cell-associated radioactivity. Results are the mean t standard deviation of at least two independent experiments performed in triplicate.
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Inhibitor
°C h
Preincubation
Inhibition
of '2sl-EGF-
binding
IgG2a 2136 (5 x 10-' M) 37 4 DME-BSA 3 ± 5
IgG2a KE-2 (2 x 10-' M) 37 5 DME-BSA 37 ± 6
37 4 DME-BSA 46 ± 6
4 4 DME-BSA 6 ± 4
37 4 DME-BSA + 10
-s M cytochalasin D 34 ± 8
37 4 DME-BSA + 10
-s M colchicin 42 ± 5
37 4 PBS-BSA + 0.1% NaN3 38 ± 6
Prefixed cells 37 4 DME-BSA 7 ± 5
IgG fraction of polyclonal Sto anti-HLA antiserum (5 x 10-6 37 4 DME-BSA 32 ± 7
M) 4 4 DME-BSA 11 ± 5EGF was rapid and temperature dependent. Preincubation of
the cellswith EGF at 37°C for 5 min was sufficientto obtain
its full effect, while saturation of the EGF receptors at 4°C
had no influence on subsequent anti-HLA antibody binding.
The inhibition ofanti-HLA antibody binding was affected at
concentrations ofEGF that are approximately half-saturating
at equilibrium.
Distribution of Fluorescently Labeled Anti-HLA
Antibodies and EGF on A-431 Cells
When fluorescently labeled EGF and KE-2 were bound to
cells at 4°C, the fluorescence of both appeared continuous
around the cell periphery. KE-2 bound at 4°C and aggregated
into coarse patches by a fluorescent anti-Ig at 37°C did not
co-patch EGF receptors (Fig. 4, A-C). Incubation of cells
with fluorescent EGF and KE-2 IgG at 37°C produced cells
with patchy internal EGF fluorescence which bound fluores-
cent anti-mouse Ig (detecting HLA) at the cell surface (Fig. 4,
D-F).
Though Fab KE-2 bound well to A-431 to 37°C (not shown)
itwasdisplaced by EGF when fluorescein Fab and rhodamine-
EGF were incubated at 37°C (compare the intensities in Fig.
5, A and B with C and D). Co-incubation of cells with
rhodamine EGF and fluorescein KE-2 Ig at 37°C yielded cells
that fluoresced strongly for fluorescein but weakly for rhoda-
mine (Fig. 5, E and F).
DISCUSSION
The binding of anti-HLA antibodies to A431 cells or to
normal fibroblasts reduced the number of receptors available
for binding by epidermal growth factor, EGF. Conversely,
EGF bound to the A-431 cells reduced the number of anti-
HLA antibodies bound. Although there are other treatments
that alter the display of EGF receptors, these generally affect
the affinity of the receptors (3, 21, 26, 31) and not their
number. Interferon-treated cells express increased levels of
MHC antigens (for example, reference 35), but this requires
long exposure, in contrast to the immediate effect of EGF on
HLA display.
The inhibitory effect of anti-HLA antibodies was specific.
Several monoclonal antibodies directed against cell surface
components of human fibroblasts other than the EGF recep-
tor did not affect the binding of EGF to its receptors. The
anti-HLA antibodies do not induce gross changes in cell
morphology. They did not affect the binding of radiolabeled
human growth hormone, Concanavalin A, or wheat germ
agglutinin to their respective membrane receptors. Our anti-
HLA antibody preparation was free of EGF contaminants
and in immunoprecipitation experiments broughtdown com-
ponents of 44,000 and 11,000 mol wt, of the size of HLA
heavy, light chains and significantly smaller than the size of
the EGF receptor on A431 cells (6, 17).
Binding of MHC antigens by anti-HLA antibodies or Fab
fragments is not sufficient to inhibit EGF binding to its
receptor. The anti-HLA antibodies must be divalent and brief
preincubation at 37°C was required. Indeed, a 5-min incuba-
tion at 37°C was more effective than a 4-h incubation with
KE-2 at 4°C. Prefixation of the cells abolished the effect of
the antibodies. The inhibition of EGF binding by the anti-
HLA antibodies was not influenced by the presence or absence
of Cal" ions or azide, nor by the treatment of cells with
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microfilament (cytochalasin D) or microtubule (colchicin)
disrupting drugs.
Only a fraction of HLA or EGF receptors must be bound
for the binding of one ligand to affect the display ofreceptors
for the other. A 5-min incubation at 37°C was sufficient to
alter receptor display, and a 4-h incubation with anti-HLA
antibody had no further effect on EGF binding. Fixed cells
did not alter EGF receptor number in response in anti-HLA,
and there was no effect ofeither EGF or anti-HLA if cells are
maintained at 4°C. Thus, the cell response to the ligand
binding may require metabolism. Sodium azide did not in-
hibit the effect of anti-HLA, but this may merely have indi-
cated that anaerobic metabolism is sufficientfor modification
of receptor display, or that cell ATP levels are reduced too
slowly to affect the response.
Only divalent anti-HLA affected a reduction in number of
EGF receptors. The Fab fragments of our monoclonal anti-
body, which bound to cellswith an affinity about 10-fold less
than the intact antibody, were ineffective even when used at
concentrations 10-fold higher than those of the intact IgG.
Fab fragments cross-linked by anti-Fab were nearly as effec-
tive as intact Ig in altering EGF binding, while high concen-
trations of intact IgG (800 kg/ml) were not so effective as
lower concentrations (80 ug/ml). Increasing the concentra-
tions ofantibody results in increasing amounts ofIg molecules
bound monovalently. Thus, cross-linking of HLA antigens
appears to be required to affect the EGF receptor. The Scat-
chard analysis of binding data shows that whereas 50% of
anti-HLA is bound divalently to otherwise untreated cells,
100% of anti-HLA is bound divalently in EGF-treated cells.
In this case, then, the apparent change in number of anti-
HLA binding sites induced by EGF may be a change in the
affinity of HLA antigens for the antibody. It is unlikely to be
the result of cell shape changes induced in A431 by EGF.
Such changes should equally reduce binding of IgG and Fab.
EGF binding is reduced 30-40% when A431 or normal
fibroblasts (HFF) were treated with anti-HLA antibody.
Though the numbers of EGF receptors and MHC antigens
are 20-fold higher on A431 than on HFF, the ratio of EGF
receptors and MHC antigens is about the same on both cell
types. The magnitude of inhibition is about the same as that
seen for inhibition of insulin and glucagon binding or cell
adhesion by anti-H-2 (1, 18) or anti-HLA (Olsson, L., C. J.
Honsik, and B. Diamant, submitted manuscript) antibodies.
One monoclonal antibody against all HLA class I heavy
chains has been an effective blocker of insulin binding (Ols-
son, L., C. J. Honsik, and B. Diamant, submitted manuscript)
(32); but even the binding of this antibody is only partly
blocked by preincubating cells with insulin.
The effects reported here and in other studies on MHC and
peptide hormone binding are small when compared with the
effects of MHC haplotype in immune responses. However, in
such responses MHC affects an amplifying system of inter-
acting cells. The magnitude of its effect depends upon the
point at which MHC antigens function in the cellular cascade.
Thus, when class I antigens serve as targets in the final steps
ofa cellular immune response, haplotype differences alterthe
response by factors of 2-4. Differences in class II products
which act early, for example in antigen presentation to am-
plifying T cell subsets, may alterresponses by a factor of 100.
In contrast, our measurements here deal with the primary
event ofhormone binding to a receptor. There is no biological
amplification ofthe primary event.FIGURE 4
￿
A431 cells were incubated with KE-2 IgG at 4°C followed by fluorescein-goat anti-mouse Ig at 37°C to patch the HLA
antigens . After this incubation the cells were labeled with rhodamine EGF at 4°C . A, fluorescein anti-Ig forms coarse patches
after incubation at 37°C; 8, rhodamine EGF gives nearly continuous, finely speckled staining on a cell with patched HLA antigens .
C, phase-contrast microscopy . Cells were labeled with rhodamine EGF and KE-2 at 4°C IgG and incubated at 37° to internalize
EGF . After incubation the cells were labeled with fluorescein-goat anti-mouse Ig and examined . D, internalized rhodamine-EGF
appears patchy and cell surfaces are not well outlined . EGF bound to cells as shown is not extractable by acetic acid and hence
is internalized . E, cells as in D but viewed for fluorescein label, detecting HLA antigens . Significant amounts of HLA remain at the
cell surface, F, phase-contrast microscopy . The shape of these cells is affected by EGF at 37°C .
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729FIGURE 5 A431 cells were incubated with mixtures of reagents of 4°C or at 37°C . (A and B) Fluorescein Fab anti-HLA +
rhodamine EGF at 4°C . A, fluorescein fluorescence ; B, rhodamine fluorescence . (C and D) Fluorescein Fab (anti-HLA + rhodamine
EGF at 37°C . C, fluorescein fluorescence ; D, rhodamine fluorescence . (E and F) Fluorescein IgG anti-HLA + rhodamine EGF at
37°C . E, fluorescein fluorescence; F, rhodamine fluorescence .
Modulation of EGF binding by anti-HLA antibody and
modulation of antibody binding by EGF appeared to require
some cell metabolism, since the effects are found only at 37°C
in unfixed cells . Continued binding ofHLA antigens by the
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antibodies is implied if the results of experiments in which
antibody was present during incubation with EGF are com-
pared with the results of the experiment in which cells were
washed after binding antibody and before binding EGF . Thisobservation, and the fact that inhibitors of patching and
capping do not block the effect of anti-HLA on EGF binding,
tell against a mechanism in which cross-linking and internal-
ization of HLA antigens lead to internalization ofEGF recep-
tors. Observations on fluorescently labeled cells also suggest
that co-internalization is not a factor in inhibiting EGF or
anti-HLA binding. Regions of internalized EGF did not flu-
oresce well for the fluorescein marker of Fab anti-HLA, while
there was little sign of rhodamine EGF in cells simultaneously
exposed to fluorescein IgG anti-HLA and rhodamine EGF.
A plausible mechanism for interaction of HLA antigens
and EGF receptors involves association of HLA heavy chains
with EGF receptor glycoproteins, and configurational changes
in both molecules. It has been suggested that EGF receptors
alter configuration after binding EGF so as to predispose
them to association with other molecules on the cell surface
(14). It is known that the antigenicity of HLA heavy chains is
altered by association with Q-2 microglobulin light chain (20)
and that this association is not stable (16). Associations be-
tween MHC antigens and hormone receptors, similar to those
between MHC antigens and viral membrane glycoproteins
(8), could alter receptor or HLA antigens so that one or the
other could no longer bind its ligand.
Our data imply that an HLA dimer is necessary to alter
EGF receptors. Inhibition of EGF binding by anti-HLA an-
tibody, then, would be due to stabilization of antigen dimers
by the antibody. Failure to inhibit EGF binding at 4°C in
fixed cells may be due to reduced associations between HLA
antigens and EGF receptors, either because reduced lateral
diffusion inhibits formation of receptor-antigen complexes,
or because cell metabolism is required to stabilize the associ-
ations.
The data presented here are the latest in a series of obser-
vations indicating that the binding of peptide hormones by
specific cell surface receptors is moduated by interaction with
histocompatibility antigens. Thus MHC haplotype ought to
affect the sensitivity of cells to hormones, either exacerbating
or mitigating the effects of hormone imbalance. We suggest
that biological relationships between peptide hormone recep-
tors and MHC antigens will be found in diabetes and perhaps
as well in host responses to tumors whose growth is driven by
transforming growth factors.
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